Blood clot risk prompts suspension of sales of Iclusig

Ariad's Iclusig, or ponatinib, has been pulled from the market less than a year after it was approved for the treatment of chronic myeloid leukemia due to the risk of blood clots, according to the FDA. The agency and Ariad will work to identify patients who can be helped by the drug, and the withdrawal is not considered permanent.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care